Literature DB >> 1399941

Post-antibiotic effects of RP 59500 with Staphylococcus aureus.

A Nougayrede1, N Berthaud, D H Bouanchaud.   

Abstract

The post-antibiotic effect (PAE) of the semisynthetic streptogramin RP 59500 was evaluated with four clinical isolates of Staphylococcus aureus (two strains susceptible to methicillin and to the macrolide-lincosamide-streptogramin B (MLSB) group and two strains resistant to these drugs). The PAE was defined as the time required for either the viable counts to increase by one log10 or for bacteria to regain their maximal rate of growth. Similar results were obtained regardless of which definition was used. For each experiment, the time of exposure of the bacteria to the drug ranged from 15-80 min. At a concentration of 0.5 x MIC and an exposure time of 80 min, RP 59500 produced a PAE in three of the four strains examined. At higher concentrations (1, 2 and 4 x MIC), a PAE was observed with all four strains. When considered as the time required for bacterial growth to return to its maximal rate, the PAE lasted for at least 7 h with the two methicillin-susceptible strains when they were exposed for 80 min to RP 59500 at 4 x MIC, compared with 5 h for the two methicillin-resistant strains and the same exposure conditions. The concentration of antibiotic was found to be a more important parameter in determining the PAE than the time of exposure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399941     DOI: 10.1093/jac/30.suppl_a.101

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  M J Rybak; H H Houlihan; R C Mercier; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

6.  Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.

Authors:  J R Aeschlimann; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.